- Home
- MYN vs SOPH Comparison
MYN vs SOPH Comparison
Compare MYN & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MYN | SOPH |
|---|---|---|
| Founded | 1992 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.1M | 374.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MYN | SOPH |
|---|---|---|
| Price | $9.99 | $4.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 125.9K | 88.5K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $23.09 |
| Revenue Next Year | N/A | $19.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.13 | $2.59 |
| 52 Week High | $10.26 | $5.70 |
Technical Indicators
Market Signals| Indicator | MYN | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 53.57 | 51.48 |
| Support Level | $9.87 | $4.54 |
| Resistance Level | $10.19 | $5.29 |
| Average True Range (ATR) | 0.09 | 0.28 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 80.85 | 71.64 |
Price Performance
Historical ComparisonAbout MYN Blackrock MuniYield New York Quality Fund Inc.
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.